GLP‐1 receptor agonists on the market are for the treatment of obesity and type 2 diabetes.[14] However, these drugs are only available for patients with the diagnosis of obesity (ICD‐10 E66) or type 2 diabetes (ICD‐10 E11), and their cost and side effects are currently limiting their broad use.[15] Hence, utilizing nutritional compounds to stimulate the release of peptides from the enteroendocrine system to diminish food intake would be a novel approach to manage appetite, and prevent overweight/obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.